The Effect of Depression on Disease Activity and Treatment Response in Patients with Inflammatory Arthritis: Results from a Narrative Literature Review

References

• Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology. 2002;41(7):793–800. doi:10.1093/rheumatology/41.7.793
   PubMed Web of Science ®Google Scholar
• Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 2006;65(6):746–752. doi:10.1136/ard.2005.045062
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE guideline [NG222]: depression in adults: treatment and management; 2022. Available from: https://www.nice.org.uk/guidance/ng222/chapter/Recommendations. Accessed June 24, 2024.
   Google Scholar
• National Institute for Health and Care Excellence. Interventional procedures guidance [IPG542]: repetitive transcranial magnetic stimulation for depression. Available from: https://www.nice.org.uk/guidance/ipg542/chapter/1-Recommendations. Accessed June 24, 2024.
   Google Scholar
• Wen KS, Zheng W. Optimization Strategies of Transcranial Magnetic Stimulation in Major Depressive Disorder. Alpha Psychiatry. 2023;24(6):270–272. doi:10.5152/alphapsychiatry.2023.231401
   PubMedGoogle Scholar
• Yuan S, Luo X, Zhang B. Individualized Repetitive Transcranial Magnetic Stimulation for Depression Based on Magnetic Resonance Imaging. Alpha Psychiatry. 2023;24(6):273–275. doi:10.5152/alphapsychiatry.2023.231412
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. TA854: esketamine nasal spray for treatment-resistant depression. Available from: https://www.nice.org.uk/guidance/ta854/chapter/1-Recommendations. Accessed June 24, 2024.
   Google Scholar
• Huang XB, Zheng W. Ketamine and Electroconvulsive Therapy for Treatment-Refractory Depression. Alpha Psychiatry. 2023;24(6):244–246. doi:10.5152/alphapsychiatry.2023.231358
   PubMedGoogle Scholar
• Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2013;52(12):2136–2148. doi:10.1093/rheumatology/ket169
   PubMed Web of Science ®Google Scholar
• Office of National Statistics. Coronavirus and Depression in Adults, Great Britain: July to August 2021; 2023.
   Google Scholar
• Vestergaard SB, Esbensen BA, Klausen JM, et al. Prevalence of anxiety and depression and the association with self-management behaviour in >12 000 patients with inflammatory rheumatic disease: a cross-sectional nationwide study. RMD Open. 2024;10(1):412. doi:10.1136/rmdopen-2023-003412
   Web of Science ®Google Scholar
• Hassamal S. Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories. Front Psychiatry. 2023;14:1130989. doi:10.3389/fpsyt.2023.1130989
   PubMed Web of Science ®Google Scholar
• Kwiatkowska B, Kłak A, Maślińska M, Mańczak M, Raciborski F. Factors of depression among patients with rheumatoid arthritis. Reumatologia. 2018;56(4):219–227. doi:10.5114/reum.2018.77973
   PubMedGoogle Scholar
• Parkinson JT, Foley EM, Jadon DR, Khandaker GM. Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management. Ther Adv Musculoskelet Dis. 2020;12:1759720X20970028. doi:10.1177/1759720X20970028
   PubMed Web of Science ®Google Scholar
• Forrest CM, Kennedy A, Stone TW, Stoy N, Darlington LG. Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv Exp Med Biol. 2003;527:287–295. doi:10.1007/978-1-4615-0135-0_32
   PubMed Web of Science ®Google Scholar
• da Fonseca LJS, Nunes-Souza V, Goulart MOF, Rabelo LA. Oxidative Stress in Rheumatoid Arthritis: what the Future Might Hold regarding Novel Biomarkers and Add-On Therapies. Oxid Med Cell Longev. 2019;2019:7536805. doi:10.1155/2019/7536805
   PubMed Web of Science ®Google Scholar
• Bajpai A, Verma AK, Srivastava M, Srivastava R. Oxidative stress and major depression. J Clin Diagn Res. 2014;8(12):CC04–7. doi:10.7860/JCDR/2014/10258.5292
   PubMedGoogle Scholar
• Bonnet CS, Williams AS, Gilbert SJ, Harvey AK, Evans BA, Mason DJ. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Ann Rheum Dis. 2015;74(1):242–251. doi:10.1136/annrheumdis-2013-203670
   PubMed Web of Science ®Google Scholar
• Serafini G, Amore M, Rihmer Z. The role of glutamate excitotoxicity and neuroinflammation in depression and suicidal behavior: focus on microglia cells. Neuroimmunol Neuroinflammation. 2015;2(3):955. doi:10.4103/2347-8659.157955
   Google Scholar
• Hodes GE, Menard C, Russo SJ. Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress. 2016;4:15–22. doi:10.1016/j.ynstr.2016.03.003
   PubMed Web of Science ®Google Scholar
• Wittenberg GM, Stylianou A, Zhang Y, et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol Psychiatry. 2020;25(6):1275–1285. doi:10.1038/s41380-019-0471-8
   PubMed Web of Science ®Google Scholar
• Pedard M, Demougeot C, Prati C, Marie C. Brain-derived neurotrophic factor in adjuvant-induced arthritis in rats. Relationship with inflammation and endothelial dysfunction. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:249–254. doi:10.1016/j.pnpbp.2017.11.006
   PubMed Web of Science ®Google Scholar
• Maiuolo J, Muscoli C, Gliozzi M, et al. Endothelial Dysfunction and Extra-Articular Neurological Manifestations in Rheumatoid Arthritis. Biomolecules. 2021;11(1):81. doi:10.3390/biom11010081
   PubMed Web of Science ®Google Scholar
• Yang X, Chang Y, Wei W. Endothelial Dysfunction and Inflammation: immunity in Rheumatoid Arthritis. Mediators Inflamm. 2016;2016:1–9. doi:10.1155/2016/6813016
   Web of Science ®Google Scholar
• De Lorenzis E, Di Giorgio A, Natalello G, et al. Depression and Endothelial Dysfunction in Psoriatic Arthritis: is There Any Possible Relationship? Front Med Lausanne. 2021;8:669397. doi:10.3389/fmed.2021.669397
   PubMed Web of Science ®Google Scholar
• Tanski W, Szalonka A, Tomasiewicz B. Quality of Life and Depression in Rheumatoid Arthritis Patients Treated with Biologics - A Single Centre Experience. Psychol Res Behav Manag. 2022;15:491–501. doi:10.2147/PRBM.S352984
   PubMed Web of Science ®Google Scholar
• Callhoff J, Albrecht K, Schett G, Zink A, Westhoff G. Depression is a stronger predictor of the risk to consider work disability in early arthritis than disease activity or response to therapy. RMD Open. 2015;1(1):e000020. doi:10.1136/rmdopen-2014-000020
   PubMedGoogle Scholar
• Deb A, Dwibedi N, LeMasters T, Hornsby JA, Wei W, Sambamoorthi U. Tumor Necrosis Factor Inhibitor Therapy and the Risk for Depression Among Working-Age Adults with Rheumatoid Arthritis. Am Health Drug Benefits. 2019;12(1):30–38.
   PubMed Web of Science ®Google Scholar
• Morris A, Yelin EH, Panopalis P, Julian L, Katz PP. Long-term patterns of depression and associations with health and function in a panel study of rheumatoid arthritis. J Health Psychol. 2011;16(4):667–677. doi:10.1177/1359105310386635
   PubMed Web of Science ®Google Scholar
• Peterson S, Piercy J, Blackburn S, Sullivan E, Karyekar CS, Li N. The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis. BMC Rheumatol. 2019;3:43. doi:10.1186/s41927-019-0092-5
   PubMedGoogle Scholar
• National Institute for Health and Care Excellence. NICE Health Technology Evaluations: The Manual. Manchester; 2022.
   Google Scholar
• Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022. doi:10.1136/ard-2022-223356
   Google Scholar
• Matcham F, Norton S, Scott DL, Steer S, Hotopf M. Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). 2016;55(2):268–278. doi:10.1093/rheumatology/kev306
   PubMed Web of Science ®Google Scholar
• Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira CM, Nardi AE, Silva AC. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry. 2013;54(8):1185–1189. doi:10.1016/j.comppsych.2013.05.010
   PubMed Web of Science ®Google Scholar
• Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). Cochrane Database Syst Rev. 2016;11(11):Cd012437. doi:10.1002/14651858.Cd012437
   PubMedGoogle Scholar
• Matcham F, Davies R, Hotopf M, et al. The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2018;57(5):835–843. doi:10.1093/rheumatology/kex528
   PubMed Web of Science ®Google Scholar
• Rathbun AM, Harrold LR, Reed GW. A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers. Clin Ther. 2016;38(7):1759–1772 e3. doi:10.1016/j.clinthera.2016.06.007
   PubMed Web of Science ®Google Scholar
• Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology (Oxford). 2009;48(9):1152–1154. doi:10.1093/rheumatology/kep170
   PubMed Web of Science ®Google Scholar
• Zhao SS, Jones GT, Hughes DM, Moots RJ, Goodson NJ. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology (Oxford). 2021;60(12):5734–5742. doi:10.1093/rheumatology/keab242
   PubMed Web of Science ®Google Scholar
• Manning-Bennett AT, Hopkins AM, Sorich MJ, et al. The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - A pooled analysis of five randomised controlled trials. Ther Adv Musculoskelet Dis. 2022;14:1759720x221111613. doi:10.1177/1759720x221111613
   Web of Science ®Google Scholar
• Nicolson SE, Caplan JP, Williams DE, Stern TA. Comorbid pain, depression, and anxiety: multifaceted pathology allows for multifaceted treatment. Harv Rev Psychiatry. 2009;17(6):407–420. doi:10.3109/10673220903463226
   PubMed Web of Science ®Google Scholar
• Lam FF, Ng ES. Substance P and glutamate receptor antagonists improve the anti-arthritic actions of dexamethasone in rats. Br J Pharmacol. 2010;159(4):958–969. doi:10.1111/j.1476-5381.2009.00586.x
   PubMed Web of Science ®Google Scholar
• Amidfar M, Khiabany M, Kohi A, et al. Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study. J Clin Pharm Ther. 2017;42(1):44–50. doi:10.1111/jcpt.12469
   PubMed Web of Science ®Google Scholar